At Carlat we dig deeper: Last fall it was the possibility of suicidality with antidepressants when we see the real data; this winter, it was the lack of clinical relevance of CYP enzyme testing when we use medications carefully; and this spring, beneath the apparent weight of thousands of studies that turn out to be flawed, we found an absence of a definable effect size for the massive $17 billion applied behavioral analysis industry.

You can't view details of this content, please login or buy subscription here